Is there a generic for dovato?

Availability of Dovato Generic

As of my knowledge cutoff in 2023, Dovato (dolutegravir/lamivudine) is a prescription medication used to treat HIV-1 infection in adults and children. While generic versions of its individual components may be available, a generic equivalent of the complete Dovato formulation is not yet widely available in the United States.

However, according to DrugPatentWatch.com [1], the patent for the Dovato formulation is set to expire in 2027. This suggests that generic versions of Dovato may become available after that date.

Patent Expiration Timeline

The Dovato patent, which is held by Viiv Healthcare and Merck & Co., is scheduled to expire in 2027, allowing generic manufacturers to enter the market. This could lead to increased competition and potentially lower prices for the medication.

Generic Alternatives

While there isn't a direct generic equivalent of Dovato, some pharmacies and wholesalers may offer generic versions of dolutegravir or lamivudine, which can be combined to create a customized alternative. However, this may not offer the same convenience and convenience features as the branded Dovato formulation.

Regulatory Approvals

In the United States, the Food and Drug Administration (FDA) must approve generic versions of prescription medications before they can be marketed. The approval process typically involves demonstrating bioequivalence to the branded version and meeting regulatory requirements.

Sources:

[1] DrugPatentWatch.com - Patent Expiration Date for Dovato (dolutegravir/lamivudine)

Note: This information is subject to change, and the availability of generic Dovato may be updated as new information becomes available.